{"transactions":[{"id":2538583,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-qualified Stock Option","published_at":"2021-10-20T20:13:16.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":4275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date."}],"balance_after":4275000,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":4275000},"source":{"system":"sec-edgar","filing":"0000899243-21-040751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321040751/doc4.xml","form_type":"4"}},{"id":2609578,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common stock","published_at":"2021-08-10T22:49:22.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors."}],"balance_after":1850688,"source":{"system":"sec-edgar","filing":"0000899243-21-032402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321032402/doc4.xml","form_type":"4"}},{"id":2609577,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common stock","published_at":"2021-08-10T22:49:22.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":75758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors."}],"balance_after":1650688,"source":{"system":"sec-edgar","filing":"0000899243-21-032402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321032402/doc4.xml","form_type":"4"}},{"id":3017771,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Non-qualified Stock Option","published_at":"2020-10-02T22:08:23.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the \"Plan\") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests annually in three equal installments beginning June 15, 2021."}],"balance_after":2000000,"derivative":{"exercise_price":3.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001807094-20-000017","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000017/primary_doc.xml","form_type":"4"}},{"id":3017770,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-10-02T22:08:23.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":1574930,"source":{"system":"sec-edgar","filing":"0001807094-20-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000017/primary_doc.xml","form_type":"4"}},{"id":3072022,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-08-04T00:59:54.000Z","date":"2020-07-31","kind":"tax_withholding","acquired":false,"shares":156570,"price":4.97,"value":778152.9,"ownership":{"direct":true},"balance_after":1074930,"source":{"system":"sec-edgar","filing":"0001807094-20-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000014/primary_doc.xml","form_type":"4"}},{"id":3072021,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-08-04T00:59:54.000Z","date":"2020-07-31","kind":"grant","acquired":true,"shares":323157,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1231500,"source":{"system":"sec-edgar","filing":"0001807094-20-000014","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000014/primary_doc.xml","form_type":"4"}},{"id":3164801,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":30933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Option grant vests in equal monthly installments over a 12-month period beginning October 7, 2019."}],"balance_after":156250,"derivative":{"exercise_price":0.39,"exercise_date":"2019-10-07","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":30933},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164800,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.63,"exercise_date":"2019-12-19","expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164799,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":187817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Option grant vests in equal monthly installments over a 12-month period beginning October 7, 2019."}],"balance_after":187183,"derivative":{"exercise_price":0.39,"exercise_date":"2019-04-07","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":187817},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164798,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.565,"exercise_date":"2019-04-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164797,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":116550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Option grant vests over a three year period beginning June 8, 2019."}],"balance_after":233450,"derivative":{"exercise_price":0.49,"exercise_date":"2019-06-08","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":116550},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164796,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164795,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.9,"exercise_date":"2019-06-18","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164794,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":199800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Option grant vests over a three year period beginning June 1, 2018."}],"balance_after":100200,"derivative":{"exercise_price":0.57,"exercise_date":"2019-06-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":199800},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164793,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2019-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164792,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":152000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2016-01-04","expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":152000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164791,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2015-11-23","expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164790,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.9,"exercise_date":"2018-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164789,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-05-04","kind":"sale","acquired":false,"shares":1201652,"price":2.7904,"value":3353089.7408,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $2.53 to $3.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":908343,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164788,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":30933,"price":0.39,"value":12063.87,"ownership":{"direct":true},"balance_after":2109995,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164787,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-05-01","kind":"sale","acquired":false,"shares":1399685,"price":3.2644,"value":4569131.714,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.13 to $3.54. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2079062,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164786,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"sale","acquired":false,"shares":2219837,"price":3.5312,"value":7838688.4144,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $3.44 to $3.74. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":3478747,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164785,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":2000000,"price":0.63,"value":1260000.0,"ownership":{"direct":true},"balance_after":5698584,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164784,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":187817,"price":0.39,"value":73248.63,"ownership":{"direct":true},"balance_after":3698584,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164783,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":1000000,"price":0.565,"value":565000.0,"ownership":{"direct":true},"balance_after":3510767,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164782,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":116550,"price":0.49,"value":57109.5,"ownership":{"direct":true},"balance_after":2510767,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164781,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":600000,"price":0.8,"value":480000.0,"ownership":{"direct":true},"balance_after":2394217,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164780,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":199800,"price":0.57,"value":113886.0,"ownership":{"direct":true},"balance_after":1794217,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164779,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":600000,"price":1.09,"value":654000.0,"ownership":{"direct":true},"balance_after":1594417,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164778,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":152000,"price":0.75,"value":114000.0,"ownership":{"direct":true},"balance_after":994417,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164777,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":325000,"price":0.87,"value":282750.0,"ownership":{"direct":true},"balance_after":842417,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3164776,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-05T01:55:17.000Z","date":"2020-04-30","kind":"exercise","acquired":true,"shares":200000,"price":0.9,"value":180000.0,"ownership":{"direct":true},"balance_after":517417,"source":{"system":"sec-edgar","filing":"0001807094-20-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000005/primary_doc.xml","form_type":"4"}},{"id":3330770,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-28T01:05:13.000Z","date":"2019-12-24","kind":"tax_withholding","acquired":false,"shares":70055,"price":0.64,"value":44835.2,"ownership":{"direct":true},"balance_after":317417,"source":{"system":"sec-edgar","filing":"0000899243-19-030134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030134/doc4.xml","form_type":"4"}},{"id":3330769,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-12-28T01:05:13.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":225983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued."}],"balance_after":387472,"source":{"system":"sec-edgar","filing":"0000899243-19-030134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030134/doc4.xml","form_type":"4"}},{"id":3333312,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Warrant (right to buy)","published_at":"2019-12-24T00:17:46.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The warrant vests upon the achievement of certain additional strategic milestones."}],"balance_after":2000000,"derivative":{"exercise_price":0.63,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0000899243-19-030010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030010/doc4.xml","form_type":"4"}},{"id":3333311,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-24T00:17:46.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2000000,"derivative":{"exercise_price":0.63,"exercise_date":"2019-12-19","expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0000899243-19-030010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030010/doc4.xml","form_type":"4"}},{"id":3396389,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (right to buy)","published_at":"2019-10-08T23:05:37.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019."}],"balance_after":375000,"derivative":{"exercise_price":0.39,"expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0000899243-19-025316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319025316/doc4.xml","form_type":"4"}},{"id":3485438,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T00:57:25.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.9,"exercise_date":"2019-06-18","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-017503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017503/doc4.xml","form_type":"4"}},{"id":3760394,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50% of the options were fully vested and exercisable as of their issuance date, and 50% of the options vest on April 8, 2019."}],"balance_after":1000000,"derivative":{"exercise_price":0.565,"expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760393,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in three equal annual installments commencing on June 1, 2019."}],"balance_after":350000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760392,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":600000,"derivative":{"exercise_price":0.8,"exercise_date":"2017-05-31","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760391,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":300000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760390,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vest in three equal annual installments commencing on June 1, 2017."}],"balance_after":600000,"derivative":{"exercise_price":1.09,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760389,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":304000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":304000,"derivative":{"exercise_price":0.75,"expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":304000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760388,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (including predecessor options) vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":650000,"derivative":{"exercise_price":0.87,"expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760387,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":200000,"derivative":{"exercise_price":0.9,"exercise_date":"2018-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760386,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":54545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":54545,"derivative":{"exercise_price":2.75,"exercise_date":"2012-03-23","expiration_date":"2022-03-23","underlying":"Common Stock","underlying_shares":54545},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760385,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":500000,"derivative":{"exercise_price":2,"exercise_date":"2015-07-31","expiration_date":"2021-07-31","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760384,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":200000,"derivative":{"exercise_price":0.64,"exercise_date":"2018-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760383,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":15750,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3760382,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-19T13:03:58.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":161489,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":161489,"source":{"system":"sec-edgar","filing":"0000899243-18-029261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029261/doc4.xml","form_type":"4"}},{"id":3762639,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"50% of the options were fully vested and exercisable as of their issuance date, and 50% of the options vest on April 8, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.565,"expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762638,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":350000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vest in three equal annual installments commencing on June 1, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762637,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2017-05-31","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762636,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762635,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in three equal annual installments commencing on June 1, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.09,"expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762634,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":304000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":0,"derivative":{"exercise_price":0.75,"expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":304000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762633,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest upon the achievement of certain strategic milestones specified in the award agreement."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2025-11-23","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762632,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.9,"exercise_date":"2018-06-30","expiration_date":"2025-06-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762631,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":54545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":2.75,"exercise_date":"2012-03-23","expiration_date":"2022-03-23","underlying":"Common Stock","underlying_shares":54545},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762630,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2015-07-31","expiration_date":"2021-07-31","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762629,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2018-05-29","expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762628,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":15750,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3762627,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":161489,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029184/doc4.xml","form_type":"4"}},{"id":3769029,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-11-13T21:33:03.000Z","date":"2018-11-08","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the options were fully vested and exercisable as of the date of the reported transaction, and fifty percent (50%) of the options will vest on April 8, 2019."}],"balance_after":1000000,"derivative":{"exercise_price":0.565,"expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-028722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318028722/doc4.xml","form_type":"4"}},{"id":3897815,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T22:02:23.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in three equal annual installments commencing on June 8, 2019."}],"balance_after":350000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000899243-18-016241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016241/doc4.xml","form_type":"4"}},{"id":3988624,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-20T10:08:09.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":120278,"price":0.69,"value":82991.82,"ownership":{"direct":true},"balance_after":161489,"source":{"system":"sec-edgar","filing":"0000899243-18-008071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318008071/doc4.xml","form_type":"4"}},{"id":3988623,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-03-20T10:08:09.000Z","date":"2018-03-15","kind":"grant","acquired":true,"shares":221711,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":281767,"source":{"system":"sec-edgar","filing":"0000899243-18-008071","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318008071/doc4.xml","form_type":"4"}},{"id":4053925,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:02:25.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":600000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-004435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004435/doc4.xml","form_type":"4"}},{"id":4053924,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:02:25.000Z","date":"2018-02-15","kind":"disposition_to_issuer","acquired":false,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.8,"expiration_date":"2018-05-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-18-004435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004435/doc4.xml","form_type":"4"}},{"id":4294816,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (right to buy)","published_at":"2017-06-05T20:40:04.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in three equal annual installments commencing on June 1, 2018."}],"balance_after":300000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-17-015331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015331/doc4.xml","form_type":"4"}},{"id":4576662,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134420,"kind":"person","name":"Pourhassan Nader","position":1,"cik":"0001532878","reported_name":"Pourhassan Nader","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-10-21T20:06:19.000Z","date":"2016-10-21","kind":"purchase","acquired":true,"shares":15000,"price":0.662,"value":9930.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.645 to $0.665, inclusive. The reporting person undertakes to provide to CytoDyn Inc., any security holder of CytoDyn Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth herein."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0000899243-16-032158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924316032158/doc4.xml","form_type":"4"}}]}